Geninus Inc is a Korea-based company principally engaged in the bioinformatics analysis business. The Company is engaged in the provision of single cell analysis services, genetic testing for disease prediction for the public, cancer genome analysis solutions based on tissue biopsy and other services. It is also engaged personal genetic testing, software development, rental business and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-11-13	₩1,368.00	+0.66%	495,910
26-11-12	₩1,359.00	-13.00%	741,565
26-11-11	₩1,562.00	+17.44%	2,241,032
26-11-10	₩1,330.00	+13.68%	797,832
26-11-09	₩1,170.00	-0.43%	937,653

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 2026-11-13			5-day change	1st Jan Change
1,368.00 ^KRW	+0.66%		+16.43%	-60.91%

03-24	GENINUS Inc. announced that it has received KRW 19.999993583 billion in funding from KB Investment Co., Ltd, Company K Partners Limited	CI
03-05	GENINUS Inc. announced that it expects to receive KRW 19.999993583 billion in funding from KB Investment Co., Ltd, Company K Partners Limited	CI

Market Cap	53.89B 40.31M 36.53M 33.79M 30.49M 57.45M 3.8B 59.48M 406M 161M 2.03B 151M 148M 6.45B	P/E 2024	-3.73x	P/E 2025	-6.72x
Enterprise Value	49.4B 36.96M 33.49M 30.98M 27.95M 52.67M 3.48B 54.52M 372M 148M 1.86B 139M 136M 5.91B	EV / Sales 2024	6.46x	EV / Sales 2025	10.7x
Free-Float	73.35%	Yield 2024 *	-	Yield 2025	-

03-24	GENINUS Inc. announced that it has received KRW 19.999993583 billion in funding from KB Investment Co., Ltd, Company K Partners Limited	CI
03-05	GENINUS Inc. announced that it expects to receive KRW 19.999993583 billion in funding from KB Investment Co., Ltd, Company K Partners Limited	CI
25-05-21	GENINUS Inc. announced that it has received KRW 10 billion in funding from AJU IB INVESTMENT Co., Ltd., Korea Investment & Securities Co., Ltd., Korea Investment Partners Co. Ltd. and other investors	CI
25-05-18	GENINUS Inc. announced that it expects to receive KRW 10 billion in funding from AJU IB INVESTMENT Co., Ltd., Korea Investment & Securities Co., Ltd., Korea Investment Partners Co. Ltd. and other investors	CI
21-11-01	GENINUS Inc. has completed an IPO in the amount of KRW 40 billion.	CI
21-07-08	GENINUS Inc. has filed an IPO.	CI

1 day	+0.66%
1 week	+16.43%
Current month	+15.64%
1 month	-21.42%
3 months	-38.24%
6 months	-65.28%
Current year	-60.91%

GENINUS Inc. Stock

Stocks

A389030

KR7389030008

Biotechnology & Medical Research

Valuation: GENINUS Inc.

Chart: GENINUS Inc.

Latest news: GENINUS Inc.

Quotes and Performance

Price Extremes

Managers and Directors: GENINUS Inc.

Latest insider transactions

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

1 week	1,135	1,614
1 month	998	1,751
Current year	998	6,480
1 year	998	6,480
3 years	998	6,480
5 years	998	6,480
10 years	998	6,483.33

Manager	Title	Age	Since
Woong-Yang Park CEO	Chief Executive Officer	63	2018-03-31
Kwan-Soo Kim DFI	Director of Finance/CFO	42	2025-02-28
Hae-Seong No CTO	Chief Tech/Sci/R&D Officer	44	2026-03-31

Director	Title	Age	Since
Woong-Yang Park BRD	Director/Board Member	63	2018-03-31
Jung-Kyu Han BRD	Director/Board Member	63	2021-06-29
Sang-Hyeok Lee BRD	Director/Board Member	63	2023-03-29

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
1/30/24	Sang-Hyeok Lee	Buy	Director	1,000	0.0030%
1/30/24	Sang-Hyeok Lee	Buy	Director	1,000	0.0030%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GENINUS INC.	+0.66%	+16.43%	-34.07%	-50.52%	40.31M
WUXI APPTEC CO., LTD.	-2.69%	-0.48%	+53.97%	+70.99%	66.33B
ARGENX SE	-0.92%	+7.67%	+12.64%	+92.55%	60.62B
LONZA GROUP AG	0.00%	+0.39%	+22.34%	+90.83%	55.5B
BEONE MEDICINES AG	+0.14%	+2.35%	+13.86%	+106.64%	47.58B
IQVIA HOLDINGS INC.	-2.21%	-2.47%	+20.18%	+32.24%	43.69B
REVOLUTION MEDICINES, INC.	-2.30%	-10.40%	+154.30%	+725.54%	37.27B
CELLTRION, INC.	+2.15%	+1.42%	+14.58%	+54.23%	36.57B
GENMAB A/S	-2.32%	-2.24%	+76.50%	+54.55%	32.22B
INSMED INCORPORATED	+2.62%	+5.90%	-37.29%	+393.72%	26.58B
Average	-0.49%	+1.74%	+29.70%	+157.08%	41B
Weighted average by Cap.	-0.83%	+0.20%	+36.62%	+155.23%

	2024	2025
Net sales	6.46B 4.83M 4.38M 4.05M 3.65M 6.88M 455M 7.12M 48.62M 19.28M 243M 18.12M 17.74M 772M	10.48B 7.84M 7.11M 6.57M 5.93M 11.18M 739M 11.57M 78.96M 31.31M 395M 29.43M 28.81M 1.25B
Net income	-12.27B -9.18M -8.32M -7.7M -6.94M -13.08M -866M -13.55M -92.45M -36.66M -462M -34.45M -33.72M -1.47B	-17.37B -13M -11.78M -10.89M -9.83M -18.52M -1.23B -19.17M -131M -51.89M -655M -48.77M -47.74M -2.08B
Net Debt	-4.14B -3.1M -2.81M -2.6M -2.34M -4.41M -292M -4.57M -31.19M -12.37M -156M -11.62M -11.38M -495M	-4.49B -3.36M -3.04M -2.81M -2.54M -4.78M -317M -4.95M -33.8M -13.4M -169M -12.6M -12.33M -537M